why choose us

First received: May 15, 2023

Clinical Trial: A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

Study Status: Completed

Recruit Status: RECRUITING

Condition: Primary Immune Thrombocytopenia (ITP)

Study Type: INTERVENTIONAL


Official Title: A Phase 2 Study to Evaluate the Efficacy and Safety of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least a Corticosteroid and a Thrombopoietin

Brief Summary: The purpose of this study is to evaluate the therapeutic efficacy, safety and tolerability of ianalumab in adult patients with primary ITP previously treated with at least one corticosteroid and one TPO-RA.

Read more